story of the week
Measurable Residual Disease Response in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
J. Clin. Oncol 2021 Dec 15;[EPub Ahead of Print], KW Pratz, BA Jonas, V Pullarkat, C Recher, AC Schuh, MJ Thirman, JS Garcia, CD DiNardo, V Vorobyev, NS Fracchiolla, SP Yeh, JH Jang, M Ozcan, K Yamamoto, A Illes, Y Zhou, M Dail, B Chyla, J Potluri, H DöhnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.